Siemens Healthineers Completes Tennessee PET Expansion as Chinese Rivals Close In

Siemens Healthineers finished a $43.6M expansion of its Rockford, Tennessee PET detector site, adding 40,000 sq ft and over 90 jobs as China pressure grows.

Siemens Healthineers has wrapped up a $43.6 million expansion of its PET detector center in Rockford, Tennessee, adding roughly 40,000 square feet to a campus that now spans 97,000 square feet. The buildout, which also included 7,500 square feet of renovated space, splits into 36,000 square feet of additional manufacturing capacity and 4,000 square feet earmarked for research and development. A separate 50,000-square-foot crystal plant at the site falls outside the scope of this project.

The Rockford facility holds a unique position within the group: according to company statements, it is the only manufacturing site worldwide for PET detectors, producing components used in PET/CT scanners. The expansion is designed to lift capacity for both domestic US demand and international shipments. Tennessee Governor Bill Lee and the state's economic development agency TNECD accompanied the announcement, and the state backed the project with a $930,000 FastTrack grant. More than 200 employees already work at the location, with over 90 additional positions to be created across the next five years.

The investment lands at a moment when molecular imaging is gaining traction. In the US, a newly formed Cardiac PET Alliance—bringing together more than 1,200 cardiologists from 101 practices—is pushing to defend patient access to cardiac PET diagnostics with payers. Studies cited by the initiative point to over 50% fewer invasive coronary interventions and roughly 30% lower total costs when the technology is used, a backdrop that could underpin demand for the components made in Tennessee.

Staffing is expanding alongside the physical footprint. Siemens Healthineers is recruiting a new Zone General Manager for the Southeast region, based in Nashville, with compensation listed between $280,000 and $385,000. The role requires at least 15 years of sales experience in medical technology and diagnostic imaging, plus roughly 70% travel within the zone.

Chinese Competition Tightens Its Grip

While capacity grows in the US, pressure is mounting in China. According to a report in Handelsblatt, Chinese medical technology manufacturers are pushing into Europe with increasingly sophisticated products, even as they enjoy policy favor at home. Western suppliers are losing market share in China as a result. For Siemens Healthineers, the report describes the competitive environment as challenging—though the company is simultaneously gaining ground in imaging and precision therapy.

The development feeds into a broader debate about China's industrial catch-up. UBS, in a recent assessment, called China's industrial ascent a bigger long-term threat to European industries than US tariff policy, explicitly naming medical technology among the affected sectors. The group posted roughly 74,000 employees and revenue of about EUR 23.4 billion in fiscal 2025, with diagnostic imaging a core pillar of the business.

Shares Stuck Below Their Highs

The stock has yet to reflect any lift from the factory news. Siemens Healthineers closed Wednesday at EUR 38.83, nearly flat versus the prior day, leaving the shares about 22% below their 52-week high of EUR 49.78 reached last October. The gap to the 52-week low set in May stands at 18%. Year-to-date the stock is down 14%, and over twelve months the decline reaches 20%. Trading close to its 200-day moving average of EUR 38.89, the equity appears to be consolidating after its recent stretch of weakness.

Beyond the US, the company continues to notch up fresh business. In London, private healthcare provider Prime Health installed a MAGNETOM Lumina 3T MRI scanner from the group as part of a GBP 2 million investment in a diagnostics center in the Harley Street Health District. Such individual installations rarely move the share price in the short term, but they underscore persistent demand for the company's imaging technology across different regions.

For investors, the day's central takeaway is industrial rather than financial: the Tennessee buildout secures additional manufacturing capacity in a growing PET diagnostics niche, even as the stock itself drifts sideways beneath its annual highs. How management balances capacity expansion in one growth market against intensifying competition in another will shape its investment decisions in the quarters ahead. Whether share gains in imaging and precision therapy can offset the structural challenges in China remains the open question.